Priority 9 from the COPD Exacerbation PSP

UNCERTAINTY: How does the presence of anxiety and depression affect the prevention, diagnosis, and treatment of COPD exacerbations? (JLA PSP Priority 9)
Overall ranking 9
JLA question ID 0104/9
Explanatory note People living with COPD often have anxiety and depression. This question seeks to better understand the relationship between anxiety, depression and exacerbations. For example, is someone with anxiety and depression more likely to develop and/or experience exacerbations in a different way, that might lead to different outcomes or the need for different treatments?
Evidence

Anxiety and depression are important comorbidities in COPD and both are associated with a poor prognosis younger age, female sex, smoking, lower FEV1, cough, higher SGRQ score, and a history of cardiovascular disease.
https://pubmed.ncbi.nlm.nih.gov/20889909/
https://pubmed.ncbi.nlm.nih.gov/15821196/
https://pubmed.ncbi.nlm.nih.gov/17210879/
https://pubmed.ncbi.nlm.nih.gov/20335292/

In summary there is no clear answered for this question.

Health Research Classification System category Respiratory
Extra information provided by this PSP
Original uncertainty examples

How to recognise the anxiety that comes with the exacerbation and how to manage it and cope with the physical illness simultaneously

Submitted by Patient
PSP information
PSP unique ID 0104
PSP name COPD Exacerbation PSP
Total number of uncertainties identified by this PSP. 51 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)
Date of priority setting workshop 1 April 2021